KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Nektar Therapeutics (NKTR) Times Interest Earned (2016 - 2020)

Nektar Therapeutics has reported Times Interest Earned over the past 11 years, most recently at -$120.11 for Q2 2020.

  • Quarterly results put Times Interest Earned at -$120.11 for Q2 2020, down 466.17% from a year ago — trailing twelve months through Mar 2021 was -$619.59 (down 2948.56% YoY), and the annual figure for FY2020 was -$62.05, down 200.5%.
  • Times Interest Earned for Q2 2020 was -$120.11 at Nektar Therapeutics, down from -$21.54 in the prior quarter.
  • Over the last five years, Times Interest Earned for NKTR hit a ceiling of $180.8 in Q2 2018 and a floor of -$120.11 in Q2 2020.
  • Median Times Interest Earned over the past 5 years was -$13.16 (2017), compared with a mean of -$7.09.
  • Biggest five-year swings in Times Interest Earned: crashed 5977.31% in 2016 and later surged 2066.6% in 2018.
  • Nektar Therapeutics' Times Interest Earned stood at -$5.79 in 2016, then rose by 26.33% to -$4.27 in 2017, then plummeted by 334.1% to -$18.52 in 2018, then decreased by 9.05% to -$20.2 in 2019, then tumbled by 494.63% to -$120.11 in 2020.
  • The last three reported values for Times Interest Earned were -$120.11 (Q2 2020), -$21.54 (Q1 2020), and -$20.2 (Q4 2019) per Business Quant data.